by The global biologics contract development market size was valued at USD 6.65 billion in 2022 and is projected to reach USD 18.71 billion by 2032, growing at a CAGR of 10.89% from 2023 to 2032, According to Precedence Research.
The global biologics contract development market boons an in-depth synopsis of the competitive landscape of the market globally, thus helping establishments understand the primary threats and prospects that players/vendors in the market are dealt with. It also incorporates thorough business profiles of some of the prime vendors in the market.
Download The Sample Copy For Better Understanding@ https://www.precedenceresearch.com/sample/3056
Biologics Contract Development Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 7.38 Billion |
| Market Size by 2032 | USD 18.71 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 10.89% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Source, By Product Service, and By Indication |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Also read: Spectrometry Market Size To Rake USD 37.48 Bn By 2032
Benefits of this market
- This study analyses the market size and share for biologics contract development along with the present trends in the industry and forecasts for the future, showing investment opportunities for the future.
- In order to compare the financial capabilities of the biologics contract development market in the present, a quantitative analysis is done of the market from 2023 to 2032.
- It is clear from this brilliant presentation of Porter’s Five Forces that buyers and suppliers have a lot of potential to gain from one another.
- It is important to understand the most profitable trends in the biologics contract development market in order to gain an advantage in the market.
- A comprehensive analysis of the driving factors, limitations, and opportunities is provided in the report, along with an in-depth analysis of the effect they have on the market.
- The report also includes the market share for biologics contract development for several significant vendors as well as the latest developments in the market.
Leading players of the global biologics contract development market are analysed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. Precedence Research provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global biologics contract development market. Furthermore, the report offers two separate market forecasts – one for the production side and another for the consumption side of the global biologics contract development market. It also provides useful recommendations for new as well as established players of the global biologics contract development market.
The major players in the market
- Abzena Ltd
- AGC Biologics
- Bionova Scientific, Inc.
- BioXcellence
- Curia Global, Inc.
- Fujifilm Diosynth Biotechnologies
- Genscript
- KBI Biopharma
- STC Biologics
- Thermo Fisher Scientific Inc.
- WuXi Biologics
- Boehringer Ingelheim Group
- Samsung Biologics
- Lonza Group
Biologics Contract Development Market Segmentations:
By Source
- Microbial
- Mammalian
- Others
By Product Service
- Cell Line Development
- Microbial
- Mammalian
- Others
- Process Development
- Upstream
- Microbial
- Mammalian
- Others
- Downstream
- Impurity, isolation, & identification
- Physicochemical characterization
- Pharmaceutical analysis
- Others
- By Product
- MABs
- Recombinant proteins
- Others
- Upstream
- Others
By Indication
- Oncology
- Immunological disorders
- Cardiovascular disorders
- Hematological disorders
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Biologics Contract Development Market
5.1. COVID-19 Landscape: Biologics Contract Development Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Biologics Contract Development Market, By Source
8.1. Biologics Contract Development Market, by Source, 2023-2032
8.1.1 Microbial
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Mammalian
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Biologics Contract Development Market, By Product Service
9.1. Biologics Contract Development Market, by Product Service, 2023-2032
9.1.1. Cell Line Development
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Process Development
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Biologics Contract Development Market, By Indication
10.1. Biologics Contract Development Market, by Indication, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Immunological disorders
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Cardiovascular disorders
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Hematological disorders
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Biologics Contract Development Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Source (2020-2032)
11.1.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.1.3. Market Revenue and Forecast, by Indication (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Indication (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Indication (2020-2032)
Chapter 12. Company Profiles
12.1. Abzena Ltd
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bionova Scientific, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioXcellence
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Curia Global, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Fujifilm Diosynth Biotechnologies
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Genscript
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. KBI Biopharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. STC Biologics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Thermo Fisher Scientific Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Key inquiries addressed in the report:
- Investigate the COVID 19 outbreak’s effects.
- Our researchers give precise responses, pinpoint significant chances and fresh investments, and suggest excellent market strategy avenues.
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
